{"DataElement":{"publicId":"3269795","version":"1","preferredName":"Biomarker Peroxisome Proliferative Activated Receptor Gamma Testing Outcome Laboratory Procedure Outcome Percentage Value","preferredDefinition":"Percentage value to represent the result of peroxisome proliferative activated receptor gamma (PPARy) testing.","longName":"PPARY_TST_PCT_VAL","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2969419","version":"1","preferredName":"Biomarker Peroxisome Proliferative Activated Receptor Gamma Testing Outcome","preferredDefinition":"Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc_A procedure for critical evaluation; a means of determining the presence, quality, or truth of something._Expressed as multiple variants in adipose tissue (highest), skeletal muscle, spleen, heart, liver placenta, lung, and ovary by human PPARG Gene (NR1/PPAR Family), nuclear Peroxisome Proliferative Activated Receptor Gamma heterodimerizes with RXRs and NCOA6 coactivator to regulate target gene transcription. A receptor that binds peroxisome proliferators, such as hypolipidemic drugs and fatty acids, PPARG is a key regulator of adipocyte differentiation and glucose homeostasis. Once activated by ligand, PPARG binds to an acyl-CoA oxidase gene promoter element, activates transcription, and controls the peroxisomal fatty acid beta-oxidation pathway. Defects in PPARG can lead to type 2 insulin-resistant diabetes and hypertension. (NCI)_Outcome; a phenomenon that follows and is caused by some previous phenomenon_","longName":"BIOMK_PPARG_TST_RSL","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2969417","version":"1","preferredName":"Biomarker Peroxisome Proliferative Activated Receptor Gamma","preferredDefinition":"Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc:Expressed as multiple variants in adipose tissue (highest), skeletal muscle, spleen, heart, liver placenta, lung, and ovary by human PPARG Gene (NR1/PPAR Family), nuclear Peroxisome Proliferative Activated Receptor Gamma heterodimerizes with RXRs and NCOA6 coactivator to regulate target gene transcription. A receptor that binds peroxisome proliferators, such as hypolipidemic drugs and fatty acids, PPARG is a key regulator of adipocyte differentiation and glucose homeostasis. Once activated by ligand, PPARG binds to an acyl-CoA oxidase gene promoter element, activates transcription, and controls the peroxisomal fatty acid beta-oxidation pathway. Defects in PPARG can lead to type 2 insulin-resistant diabetes and hypertension. (NCI)","longName":"C16342:C34077","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biomarker","conceptCode":"C16342","definition":"A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Peroxisome Proliferator-Activated Receptor Gamma","conceptCode":"C34077","definition":"Peroxisome proliferator-activated receptor gamma (505 aa, ~58 kDa) is encoded by the human PPARG gene. This protein plays a role in transcriptional regulation, lipid metabolism, cell differentiation, glucose homeostasis and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AC109C2-2FE5-5C6A-E040-BB89AD4314B5","latestVersionIndicator":"Yes","beginDate":"2009-12-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-15","modifiedBy":"ONEDATA","dateModified":"2009-12-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2527278","version":"1","preferredName":"Testing Result","preferredDefinition":"A procedure for critical evaluation.:Outcome; a phenomenon that follows and is caused by some previous phenomenon.","longName":"C15336:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testing","conceptCode":"C15336","definition":"A procedure for critical evaluation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F9F4B5C-5E58-18D6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-12","modifiedBy":"ONEDATA","dateModified":"2006-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AC109C2-2FF3-5C6A-E040-BB89AD4314B5","latestVersionIndicator":"Yes","beginDate":"2009-12-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3061015","version":"1","preferredName":"Laboratory Procedure Outcome Percentage Integer::0 Decimal Place Value","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The result of an action._A fraction or ratio with 100 understood as the denominator._A number with no fractional part, including the negative and positive numbers as well as zero.::0_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A numerical quantity measured or assigned or computed.","longName":"3061015v1.0","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","format":"%","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3061014","version":"1","preferredName":"Laboratory Procedure Outcome Percentage Integer::0 Decimal Place Value","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.:Outcome; a phenomenon that follows and is caused by some previous phenomenon.:Percentage; a fraction or ratio with 100 understood as the denominator.:A number with no fractional part.::0:An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers.:A numerical quantity measured or assigned or computed.","longName":"C25294:C20200:C25613:C45255::0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Decimal Place","conceptCode":"C42646","definition":"An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8446A1A4-4444-2A88-E040-BB89AD43255A","latestVersionIndicator":"Yes","beginDate":"2010-04-15","endDate":null,"createdBy":"WHITES","dateCreated":"2010-04-15","modifiedBy":"ONEDATA","dateModified":"2010-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8446A1A4-4455-2A88-E040-BB89AD43255A","latestVersionIndicator":"Yes","beginDate":"2010-04-15","endDate":null,"createdBy":"WHITES","dateCreated":"2010-04-15","modifiedBy":"NYCHM","dateModified":"2010-12-02","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812571","version":"1","longName":"Lombardi Cancer Center","context":"NCIP"},{"publicId":"2812605","version":"1","longName":"Lombardi New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Percent Expression (0-100%)","type":"Preferred Question Text","description":"Percent Expression (0-100%)","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AC46B303-4010-EC24-E040-BB89AD431A2A","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"REEVESD","dateModified":"2015-05-19","changeDescription":"Curated to support Lombardi Cancer Center clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}